Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 19/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28011916 | 0.89 | NR1H2 (0.54) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL12960975 | 0.87 | NR1H2 (0.57) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL15231418 | 0.87 | NR1H2 (0.58) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL24893884 | 0.86 | NR1H2 (0.56) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL31370431 | 0.86 | NR1H2 (0.66) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL28006421 | 0.85 | NR1H2 (0.55) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL5639367 | 0.84 | L3MBTL1 (0.43) | NR1H2 | |
| SCHEMBL31370842 | 0.84 | NR1H2 (0.60) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL31095612 | 0.84 | NR1H2 (0.43) | NR1H2NR1H3 | |
| SCHEMBL28459423 | 0.84 | NR1H2 (0.57) | NR1H2NR1H3CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104557874-B | Quinoline amido indyl zinc, magnesium, calcium compounds and its preparation method and application | 华东理工大学 | 2017-01-04 | — | — | CN | disclosed |
| WO-2008137805-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20070244128-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244128-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | NR1H2 1451/4885NR1H3 1925/4885CA12 4860/4885 |
| US-20070244128-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | NR1H2 1451/4885NR1H3 1925/4885CA12 4860/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | NR1H2 1451/4885NR1H3 1925/4885CA12 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.